Home Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease
 

Keywords :   


Eleven Biotherapeutics Completes Enrollment In Pivotal Phase 3 Study Of EBI-005 in Patients With Dry Eye Disease

2014-11-05 05:46:07| drugdiscoveryonline Home Page

Eleven Biotherapeutics, a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, recently announced the completion of patient enrollment in its first pivotal, Phase 3 clinical study of EBI-005 in patients with dry eye disease

Tags: with study eye phase

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
24.11Costume
24.11BB S604ULS
24.1133
24.11 ElectronicAudioExperimentsDude Incedible
24.11 TC101 5IP 6 NS.NEO 950GH S
24.11
24.11
24.11
More »